Table 2.
Characteristics of patients demonstrating LGE
| Patient number | Age | Time from EOT to CMR (mos) | Cancer site | LGE volume (cc) | Dmean EQD2 (Gy) to LGE | Dmean EQD2 (Gy) to heart | Dmax EQD2 (Gy) to LGE | Dmax EQD2 (Gy) to heart | D95 EQD2 (Gy) to LGE |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 87 | 28.3 | lung | 2.4 | 6.7 | 4.5 | 28.2 | 41.3 | 0.7 |
| 2 | 50 | 7.7 | lung | 0.2 | 16.5 | 4.7 | 25.5 | 48.8 | 0.9 |
| 3 | 67 | 22.1 | lung | 5.5 | 12.0 | 6.8 | 43.1 | 108 | 1.3 |
| 4 | 67 | 14.2 | breast | 1.0 | 12.4 | 1.8 | 16.1 | 40.8 | 8.7 |
| 5 | 65 | 2.2 | breast | 6.1 | 1.7 | 2.3 | 3.7 | 51.3 | 0.9 |
| 6 | 60 | 11.9 | lung | 2.2 | 0.4 | 4.1 | 0.5 | 66.6 | 0.3 |
| 7 | 71 | 26.5 | esophagus | 2.1 | 6.1 | 8.8 | 16.6 | 51.9 | 2.2 |
| 8 | 56 | 2.2 | lung | 0.5 | 10.9 | 21.8 | 13.2 | 69.9 | 9.1 |
| 9 | 74 | 6.0 | lung | 0.7 | 0.6 | 6.2 | 0.7 | 68.8 | 0.5 |
| Average (Range) | 66 (50–87) | 13.4 (2.2–28.3) | – | 2.3 (0.2–6.1) | 7.5 (0.4–16.5) | 6.8 (1.8–21.8) | 16.4 (0.5–43.1) | 60.8 (40.8–108.0) | 2.7 (0.3–9.1) |
* Cc cubic centimeters, CMR cardiac magnetic resonance imaging, Dmax maximum dose, Dmean mean dose, D95 minimum dose to 95% of the LGE volume, EOT end of treatment date, EQD2 equivalent dose in 2Gy fractions, Gy Gray, LGE late gadolinium enhancement, mos months